The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLMC 2020 | MM: Are anti-BCMA immunotherapies ready for the frontline?
Adriana Rossi, MD, Weill Cornell Medical College, New York City, NY, discusses on B-cell maturation (BCMA) targeted therapies in the treatment of multiple myeloma (MM). Dr Rossi highlights the status and roles of chimeric antigen receptor (CAR) T-cell therapies, bispecific T-cell engagers (BiTEs) and antibody-drug conjugates (ADCs). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Disclosures
Consulting for Amgen, BMS, Janssen
